Loading
Latest filing published 22 May 2023 for RVL Pharmaceuticals plc, €4,503.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by James Schaub on record concern RVL Pharmaceuticals plc, in the capacity of chief executive. Between 24 January 2019 and 18 May 2023, the trades on record add up to 11 filings.
Purchases make up the whole of the open-market record (2 purchases, €317k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants.
The newest entry dates from 22 May 2023: a share grant of €4,503, in RVL Pharmaceuticals plc. The last insider purchase was made public on 9 August 2022, 1,537 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations